A recent study released by researchers from Pohang University of Science and Technology (POSTECH) opens the door for more effective diabetes research and treatment. The new approach leverages ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Julia Anthony from SOLUtion Medical emphasizes usability and patient-centric design for the company’s dual chamber prefilled ...

Supplying every AED first-aid box with epinephrine auto-injectors and naloxone can significantly increase survival rates. The opioid epidemic has persisted for a long time, and treating ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Impact of Trump’s tariffs on IT companies’ demand outlook, why kirana share in FMCG declining decoded, inward remittance data ...

and GLP-1 (glucagon-like peptide-1) hormone receptors which eventually help with obesity, overweight and type 2 diabetes. According to the company, the injection is supposed to be taken once every ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

The issuer is solely responsible for the content of this announcement.

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Income Tax department has completed the regular assessment under Section 143(3) and passed assessment order pertaining to AY ...